

Current Report

Current Report as per - *Art 226 of Law no. 297/2004 and Art. 113 of CNVM Regulation no. 1/2006*

Report date: - *02.11.2016*

Name of issuing entity - *S.C. ZENTIVA S.A.*

Registered headquarters: - *50 Theodor Pallady Blvd., Bucharest*

Tel/fax number: - *021-3047200 /021-345.40.04*

Sole registration code: - *336206*

No. of registration with the Trade Registry: *J/40/363/1991*

Subscribed paid-in share capital - *41,696,115 RON*

Regulated market on which the issued securities are traded: - *Bucharest Stock Exchange*

Important event to report:

S.C. Zentiva SA informs with regard to Sanofi press release related to the decision to initiate a carve-out process in order to divest its Generics business in Europe, having the following content:

“Sanofi in Romania: We continue to operate our business as usual, upholding our commitments to patients and customers in the country

Romania, Bucharest – 02.11.2016 - As announced in our strategic roadmap 2020, [Sanofi](#) has carefully reviewed all strategic options and has decided to initiate a carve-out process in order to divest its Generics business in Europe.

The Sanofi European generics business, including Romania, is solid and profitable, ranking within the top 10 companies and is expected to remain so. However, to continue to keep succeeding in the European generics marketplace on long term, there is a need to further expand the business models and capabilities. This is why Sanofi has taken the decision to look for a buyer who would take this successful business to the next level and position it for mid and long-term sustainable growth.

Emmanuelle Valentin, General Manager Sanofi in Romania:

“Until the disposal of this activity that is expected to happen in 2018, we do not anticipate any significant changes nor impacts on our local commercial and industrial activities nor on our existing portfolios, including generics. We will continue to operate our business as usual and we will maintain our production and development plans for the Bucharest plant. We remain fully committed to delivering the best possible service to our customers and we are upholding our commitments towards Romanian patients’ needs.”

Disclaimer – it is too early to comment on any other specifics that are fully dependant on the identification of the future buyer and the divestment structure. Future communication will be ensured when new aspects will become available.

About Sanofi Generics

Sanofi is committed to provide patients around the world with reliable access to valuable and affordable high-quality, safe and effective medicines.

In addition to being effective therapies, generic medicines also play an important role by enabling healthcare systems to invest savings in the development of future, innovative treatments.

Sanofi Generics operates on a worldwide scale with its already established generic brands Zentiva, Medley, Genfar, Winthrop and Globalpharma.

Sanofi Generics market 700 molecules globally with the main therapeutic areas being CNS, Cardiovascular, Respiratory, Diabetes, Infectious diseases, male/female health and Oncology.

Its nine generics manufacturing sites produce over 900 million boxes per year.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#))."

SC ZENTIVA SA

Emmanuelle Valentin

Chairman of the Board of Directors

